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Comparison of Long-Term Oral Anticoagulation Therapies
Including Newly Approved Reversal Agent for Dabigatran
Mackenzie De Vine, Natalie Lennartz, Michaela Wolford, Rebecca Worden, Joelle Farano, Erin Petersen, PharmD, BCPS

Abstract
Anticoagulants are a well-known class of agents essential for
the prevention of blood clots, which may further develop into
deep vein thrombosis, pulmonary embolism or stroke. Individuals at a high risk of clotting, such as those with atrial fibrillation, multiple risk factors or recent hip/knee surgery,
are in need of long-term anticoagulation therapy. The purpose of this review is to highlight the pros and cons for each
available anticoagulant as well as discuss pivotal clinical trials that evaluated the safety and efficacy of these agents.
Warfarin, the oldest anticoagulant, requires the patient to
attend frequent appointments with a health care professional in order to test their international normalized ratio (INR).
Newer anticoagulants, including dabigatran, rivaroxaban and
apixaban, do not require frequent INR testing and have a
quicker onset of action than warfarin, providing convenience
for the patient. However, many health care professionals prefer warfarin because the INR may indicate its efficacy, its
dosages can be easily changed and it is typically more affordable. Additionally, dabigatran may be chosen because it is the
only one of these drugs that has a reversal agent, which can
be utilized in the case of major bleeding or emergent surgery.
There are many opportunities for pharmacists to impact patient outcomes in the anticoagulation therapy setting. From
clinics to the community pharmacy setting, the pharmacist's
role in patient counseling and education is crucial in reducing mortality. Additionally, drug development is a growing
market as reversal agents are needed for many of these newer anticoagulation therapies.

Key Terms

Warfarin; Apixaban; Dabigatran; Rivaroxaban; Idarucizumab;
Pharmacist, Anticoagulation; Vitamin K, Pulmonary Embolism; Deep Vein Thrombosis; Factor Xa; INR; Myocardial Infarction; Stroke
Introduction
Thromboemboli often follow the abnormality of at least two
of the three factors included in Virchow's triad.1 The triad
includes hypercoagulability, stasis and vascular endothelial
injury damage as the three most important anomalies in determining a patient's risk of developing a blood clot. A
CHADS2 score is used in atrial fibrillation patients to assess
their risk for stroke and eligibility for anticoagulation therapy.2 Factors in this assessment include congestive heart failure (1 point), hypertension (1 point), age 75 years and older
(1 point), diabetes mellitus (1 point), and prior stroke or
transient ischemic attack (2 points). Anticoagulation therapy
should be considered in patients scoring one point and
should be recommended in patients scoring two or more
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points. Some thromboembolic disorders are congenital,
innate or recurring.1 Risks factors of clot formation also
include pregnancy, obesity, immobility for long periods of
inactivity, smoking, oral contraceptives, trauma, surgeries,
autoimmune disorders, hormone therapy, inflammatory
disorders, age, heart valve replacements, postsurgery, congenital heart defects and other coagulation and heart-related
disorders.1,3,4 With many risk factors, and the commonality of
their prevalence, the need for an easily managed anticoagulant therapy is important for many patients.4
As described by the Virchow's triad, clot formation predominantly occurs when the triad is compromised which is especially
common after stasis and/or venous injury, two usual events that
occur post-op.s Following vascular injury, factors of the coagulation process become exposed and initiate the clotting cascade
allowing platelets to adhere to vascular endothelium and become activated. Upon activation, successive platelets aggregate
via platelet adhesion receptors resulting in thrombus formation.
The aggregation of clotting factors and platelets causes a
blood clot which, if large enough, can cause blockage of blood
flow through the vesseJ.s These clots can form in the peripheral extremities causing deep vein thrombosis (DVT) or can
become dislodged and enter the lungs causing pulmonary
embolism (PE). In the United States, venous thromboembolism (VTE) causes more than 300,000 admissions to
hospitals every year, and PEs are responsible for death in
approximately 12 percent of hospitalized patients claiming
the lives of 50,000 to 250,000 patients every year. 4 In a
study conducted by O'Reilly, Burgess and Zicat including
5,999 patients undergoing total knee replacement (TKR),
total hip replacement (THR) or bilateral TKR while on DVT
prophylaxis, the prevalence of DVT was 25.6 percent, 8.9
percent and 36.9 percent, respectively.6 In the same study,
symptomatic PE was present in 1.9 percent of all patients,
and the prevalence of fatal in-hospital PE was 0.05 percent.
Anticoagulant therapy is common in patients with atrial
fibrillation (AF), a common type of heart arrhythmia.7
Arrhythmias include the heart beating too fast, too slow or
irregularly; more specifically, AF is caused by an irregular
conduction of the atrial chambers allowing them to fibrillate.
Atrial fibrillation increases the risk of stroke, which may be
reduced with anticoagulation therapy. To prevent these serious outcomes, anticoagulant therapy can be very beneficial.
The goal of this article is to summarize the various anticoagulant therapies and emphasize the value of reversal agents,
especially the new reversal agent, idarucizumab (Praxbind),
for the anticoagulant dabigatran (Pradaxa®).
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Warfarin
Warfarin was approved in the United States in 1954, making
it one of the oldest drugs still used therapeutically today.a
Warfarin was discovered in the 1920s after a bout of cattle
disease named "sweet clover disease."9 During the Great Depression, moldy hay, which unknowingly contained molds
such as Penicillium nigricans and Penicillium jensi, was fed
to cattle causing severe hemorrhagic bleeding resulting in
death of the cattle. Two veterinary surgeons, Schofield and
Roderick, found that avoiding the moldy sweet clover hay
prevented the bleeding effects in cattle. Roderick later discovered that the acquired coagulation disorder was caused
by a "plasma prothrombin defect" and, for the next 10 years,
farmers avoided feeding their cattle sweet clover hay in fear
of the bleeding disorder. Eventually Karl Link and his student, Wilhelm Schoeffel, isolated the causative agent that is
now known as dicoumarol. Dicoumarol was found to be
formed by oxidation of natural coumarin in the moldy hay. In
1945, Link used the derivative as a rodenticide that killed
rodents by causing internal hemorrhage. After success as a
rodenticide, the transition to a compound with clinical application under the name "Coumadin" began.

Warfarin, the generic of Coumadin, is an anticoagulant that
functions by competitively inhibiting the vitamin K epoxide
reductase (VKOR) complex which works by reactivating inactive vitamin K to active vitamin K, thus depleting active vitamin K_10 With decreased active vitamin K, synthesis of active
clotting factors is reduced causing diminished coagulation
effects of the blood.
Warfarin is approved for prophylaxis and treatment of
thromboembolic complications, which include valvular and
nonvalvular atrial fibrillation; mechanical prosthetic cardiac
valves; prophylaxis and treatment of venous thrombosis and
its extension, including PE; and as adjunct therapy in reducing the risk of systemic embolism following a myocardial
infarction (MI).a.10
Warfarin is dosed anywhere between 1 mg and 10 mg daily.a
Dosing varies on hepatic impairment, vitamin K intake,
chronic heart failure (CHF), age, and functional variants of
CYP2C9 (*2 or *3 alleles) or VKORCl (-1639 polymorphism).10 Full therapeutic effects of warfarin are typically
seen five to seven days after beginning therapy which generally requires bridging therapy overlap with low molecular
weight heparin (LMWH) or unfractionated heparin for at
least five days and with an international normalized ratio
(INR) of 2 or higher for at least 24 hours.
The major adverse reactions of warfarin are fatal and nonfatal hemorrhage from any tissue or organ, and the most severe are spontaneous intracranial hemorrhage (ICH) and
gastrointestinal (GI) bleeding.10 Warfarin use should be
avoided as the monotherapy in treating heparin induced
thrombocytopenia (HIT) as warfarin initially inhibits the
synthesis of Protein C, the body's own anticoagulant factor,
and possibly accelerates the thrombotic process. Warfarin is
considered pregnancy category D or X as warfarin crosses
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the placenta, and incidents of teratogenic effects have been
reported in exposure after the first trimester, and central
nervous system (CNS) events to the fetus have been observed while taking warfarin in any trimester. In most cases,
warfarin is contraindicated in pregnancy, except in women
with mechanical heart valves where the possible benefits of
warfarin should be weighed against the risks and risks/
benefits of switching to another anticoagulation therapy.
Warfarin has a narrow therapeutic index, and several factors,
including other medications and alterations in diet, can play
a role in the extent of clotting factor inhibition; therefore,
anticoagulation must be carefully monitored.a An INR increased by 2 to 3.5 times normal should be achieved to balance between preventing thrombosis and avoiding major
bleeding complications.ii International normalized ratio
should be monitored at least every one to four weeks depending on INR consistency or variations including recent
warfarin dose, medication, disease and diet changes.a When
other products that affect warfarin are initiated, discontinued or taken irregularly, additional INR testing should be
performed. It is also important to note that whole blood clotting and bleeding times are not effective in measuring and
monitoring warfarin therapy, and an INR greater than 4 generally does not provide an additional benefit and is often associated with increased bleeding risk.lo
Before starting a new prescription or over-the-counter medication, a patient should discuss the risks with a trusted
health care professional as some medications can affect INR
and require more frequent blood testing.1 2 Patients should
avoid aspirin, unless instructed otherwise by a physician, as
this may increase a patient's bleeding risk. Other medications
that can interact with warfarin include antibiotics, pain medicines such as nonsteroidal anti-inflammatory drugs
(NSAIDs), and acid reflux medications such as cimetidine.
Some foods may also alter the effects of warfarin.10 Excessive
acute consumption of alcohol (binge drinking) should be
avoided in patients taking warfarin as it decreases the metabolism of oral anticoagulants and increases prothrombin
time (PT) and INR, whereas, chronic alcohol use may increase the metabolism of anticoagulants and decrease PT and
INR. Patients taking warfarin should maintain a consistent
diet because the effects of warfarin are decreased with an
increase of vitamin K intake. Foods, especially green leafy
vegetables, are high in vitamin K, and changes in ingestion of
these foods may alter warfarin effects. Patients should do
their best to take their warfarin medication at the same time
every day to maintain consistency in their therapy.
In cases of warfarin overdose, patients may have extensive
bleeding requiring reversal. In excessive bleeding, warfarin
should be discontinued and vitamin Ki may need to be administered parenterally.a Urgent warfarin reversal may also
require fresh frozen plasma (FFP) or prothrombin complex
concentrates (PCC). The 2015 American Heart Association/
American Stroke Association (AHA/ASA) Guidelines on intracerebral hemorrhage (ICH) compares FFP, PCC and re-
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combinant activated factor Vila (rFVIIa) as potential therapies with the use of vitamin Kin reversal of warfarin induced
over-anticoagulation.13 Congruent recommendations are
found in the 2012 CHEST Guidelines on Evidenced-Based
Management of Anticoagulant Therapy. The CHEST
Guidelines advise the administration of vitamin K in overanticoagulated patients as follows: patients with an INR
between 4.5 and 10 and no evidence of bleeding should not
be given vitamin K, patients with an INR of 10 or higher with
no evidence of bleeding should be given oral vitamin K, and
patients with major bleeding associated with warfarin
should undergo rapid reversal of anticoagulation with PCC
rather than plasma and with vitamin K 5 mg to 10 mg administered by slow intravenous injection.2
Dabigatran
Dabigatran etexilate (Pradaxa), is a direct thrombin inhibitor.14 It was approved by the U.S. Food and Drug Administration (FDA) in 2010 for use in DVT, PE, nonvalvular atrial fibrillation and postoperative thromboprophylaxis. Dabigatran
etexilate is a prod rug which is converted into its active form,
dabigatran. Dabigatran reversibly inhibits thrombin which is
both free and fibrin-bound, preventing thrombin's endogenous activity of cleaving fibrinogen to fibrin, activating clotting factors V, VII, XI, Xlll and promoting platelet aggregation.
The inhibition of these functions leads to the inhibition of
clot formation.
Four studies were credited with the approval of dabigatran
by the FDA. The first study, Dabigatran versus Warfarin in
the Treatment of Acute Venous Thromboembolism (RECOVER) was a randomized, double-blind, double-dummy,
noninferiority trial comparing oral dabigatran to warfarin. 1s
Patients enrolled in the study had acute venous thromboembolism and were initially treated with parenteral anticoagulation medication for a median of nine days prior to the
initiation of oral therapy with either dabigatran or warfarin.
Dabigatran was dosed at 150 mg twice daily while warfarin
was dosed per patient to achieve an INR between 2.0 and 3.0.
The study included 2,550 patients with 1,275 patients in
each treatment arm. 1s Patients were started on oral therapy,
assessed seven days later, and then continually checked once
monthly for a total of six months. The primary outcome was
the incidence of venous thromboembolism and related death.
Within the six month treatment period, 30 patients in the
dabigatran arm and 27 in the warfarin arm experienced the
primary outcome. This was not a statistically significant difference, determining dabigatran's noninferiority to warfarin.
Treatment of Acute Venous Thromboembolism with
Dabigatran or Warfarin and Pooled Analysis (RE-COVER II)
was a randomized, double-blind, double-dummy trial that
was designed after the conclusion of the RE-COVER study to
confirm the findings.16 The patients in the trial had been diagnosed with an acute venous thromboembolism and had
been treated with heparin for five to 11 days prior to initiation of the study. Dabigatran was dosed at 150 mg twice daily, and warfarin was dosed per patient to achieve an INR
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between 2.0 and 3.0. The primary outcome of the study was
the recurrent incidence of venous thromboembolism and
related death. Results of the study showed noninferiority of
dabigatran to warfarin due to the 30 positive outcomes
(recurrent venous thromboembolism and/or related death)
of the dabigatran group and the 28 of the warfarin group.
These treatment arms were not statistically significant proving noninferiority of dabigatran to warfarin.
The Extended Use of Dabigatran, Warfarin or Placebo in Venous Thromboembolism (VTE) is an article compiling the
results of the RE-MEDY and RE-SO NATE trials.17 RE-MEDY, a
randomized and double-blind trial, treated patients with
dabigatran 150 mg twice daily or with warfarin dosed per
patient to achieve an INR between 2.0 and 3.0. The primary
efficacy outcome was venous thromboembolism or related
death. The study included 2,866 patients who had been diagnosed with VTE and treated with anticoagulation therapy for
three months prior to initiation of the study. Within the
study, 26 patients experienced a VTE or VTE-related death in
the dabigatran arm and 18 patients in the warfarin arm. Although the dabigatran treatment group produced more VTE
or related deaths, the two treatment arms were not statistically significant, concluding that dabigatran was noninferior
to warfarin.
RE-SONATE, another randomized and double-blind trial,
compared the treatment of 150 mg of dabigatran twice daily
to placebo.17 The study included 1,343 patients previously
diagnosed with a VTE and treated with anticoagulation therapy for three months prior to trial initiation. The patients
were selected through expert opinion to be included in the
RE-SONA TE trial over the RE-MEDY trial if they were considered low-risk patients who were thought to be able to withstand placebo treatment. The primary outcome of the study
was recurrent VTE or related death. Recurrent venous
thromboembolism occurred in three patients in the dabigatran group and 37 of the patients in the placebo group. These
results were statistically significant, concluding that dabigatran is more effective than placebo at preventing a recurrent
VTE. Additionally, major bleeding occurred in 36 patients in the
dabigatran group and only 12 patients within the placebo group
(95 percent confidence interval (CI), 1.52 to 5.60 and P=0.001).
Dabigatran dosing for DVT and PE is identical and instructs
to administer one 150 mg capsule twice daily, directly following five to 10 days of parenteral anticoagulation therapy.14 Dabigatran is also dosed at 150 mg twice daily for the
treatment of nonvalvular atrial fibrillation. For the postoperative thromboprophylaxis following hip and knee replacements, 110 mg of dabigatran is administered one to four
hours after completion of surgery. If the patient is not started
on dabigatran the day of surgery, it should be initiated when
homeostasis is achieved and should be given 220 mg once
daily. The maintenance dose is also 220 mg once daily and
can be given for up to 28 to 35 days.
Most common side effects associated with the use of
dabigatran include hemorrhage and gastrointestinal symp-
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toms such as dyspepsia or gastritis-like symptoms. 14 Less
common adverse drug reactions include wound discharge,
hematuria, anemia, hematoma, increased serum alanine
aminotransferase (ALT), anaphylaxis and angioedema.
Therefore, an allergy to dabigatran presents a large risk to
patients. Additionally, it is important to determine the patient's renal function prior to the initiation of therapy and
periodically throughout treatment or when clinically indicated. No exact recommendation for the frequency ofrenal function is provided. Routine coagulation tests, on the other
hand, are not required but can be used if the medical team
wishes to determine the levels of dabigatran in the blood and
the level of therapy the patient is receiving. Such tests include activated partial thromboplastin time (aPTT), ecarin
clotting test (ECT) or thrombin time (TT).
Praxbind, generic name idarucizumab, is a monoclonal antibody which was developed as a reversal agent of
dabigatran.1 4 Idarucizumab for Dabigatran Reversal (REVERSE AD) was the study that lead to the approval ofidarucizumab by the FDA.18 The RE-VERSE AD was a prospective
cohort study that included 90 patients, split into two groups,
who all received idarucizumab for the reversal of dabigatran.
The first group consisted of patients who were taking
dabigatran and experiencing uncontrollable or lifethreatening bleeding, while the second group was composed
of patients who were in need of emergent surgery. The primary end point of the study was the maximum percentage of
reversal for dabigatran by 5 g dose of idarucizumab given IV.
The normalized results of the study concluded that 88 to 98
percent of the patients experienced a reversal of dabigatran
within minutes. In 79 percent of patients, unbound dabigatran concentrations continued to remain below 20 ng/ml
for 24 hours following idarucizumab administration. Within
the study, only one patient experienced a thrombotic event
after receiving the reversal agent. Due to the emergent need
and high efficacy displayed, idarucizumab was approved by
the FDA in 2015.19
ldarucizumab is indicated as a reversal agent for dabigatran
in the incidence of emergent surgery or if the patient has uncontrolled or life-threatening bleeding.14 The humanized
monoclonal antibody fragment binds to both dabigatran and
its acylglucuronide metabolites. Its affinity to dabigatran is
approximately 350 times greater than that of thrombin,
therefore inhibiting dabigatran within minutes.
Idarucizumab adult dosing is 5 g IV as two separate 2.5 g
doses, administered no more than 15 minutes apart.14 If the
patient still has elevated coagulation parameters after the
initial 5 g dose, an additional 5 g dose may be given. The
most common side effects include delirium, headache,
hypokalemia, constipation, pruritus, pneumonia and fever.
Hypersensitivity symptoms may also occur such as rash, hyperventilation and pruritus.
Rivaroxaban
Rivaroxaban (Xarelto®) was approved as an anticoagulation
therapy by the FDA in 2011. It was the first novel oral antico-
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agulant (NOAC) approved, nearly 50 years after the approval
of warfarin. 20 Rivaroxaban is an oral direct factor Xa inhibitor that works by prolonging activated thromboplastin time
and increasing levels of anti-factor Xa. This medication is
indicated for the treatment and prophylaxis of PE and DVT in
patients who have undergone surgeries such as knee or hip
replacement and patients diagnosed with nonvalvular atrial
fibrillation. Currently, this therapy is being studied in the
treatment of acute coronary syndromes.
Rivaroxaban was compared to warfarin in a multi-center,
randomized, double-blind, double-dummy, event-driven trial
including 14,264 patients with nonvalvular atrial fibrillation
with an increased risk of stroke in the ROCKET AF triaJ.21 The
study recognized that vitamin K antagonists, like warfarin, are
beneficial in patient populations with nonvalvular atrial fibrillation and increased risk of stroke. However, the increased
monitoring, dosing adjustments, and food and drug interactions, among other requirements, certainly demonstrated a
need for a more convenient and manageable patient therapy.
Rivaroxaban was targeted in this study as a once daily anticoagulant with the potential to provide a more consistent, predictable and convenient therapy as opposed to warfarin. The
study compared rivaroxaban with dose-adjusted warfarin in
patients with the previously mentioned indications for the
prevention of stroke and systemic embolism.
Patients were identified as having a moderate-to-high risk of
stroke if they had a history of previous stroke, transient ischemic attack or systemic embolism (SE) with either heart
failure, left ventricular ejection fraction .s 35 percent, hypertension, diabetes or were at least 75 years of age.21 Patients
were then randomly assigned to either receive a fixed once
daily dose of rivaroxaban in the evening (20 mg or 15 mg
based on CrCl of 30 to 49 mL/min) or adjusted warfarin
(target INR 2.0-3.0). The primary endpoints included hemorrhagic or ischemic stroke and systemic embolism. Secondary
endpoints consisted of stroke, SE or death from cardiovascular causes; a composite including the previous or Ml; and
individual components of the endpoints. Safety endpoints
measured were composites of major and minor bleeding.
Primary analysis was used to conclude rivaroxaban's noninferiority to warfarin, and secondary analysis was used to
conclude superiority.
Over a span of three years, 14,264 patients were randomized.21 The median age of patients was 73 years, and patients
also had substantial comorbid conditions including hypertension, heart failure and diabetes. The per-protocol population demonstrated significant differences in the primary
outcome of stroke or systemic embolism (P<0.001). In the
rivaroxaban group, only 188 events occurred in the 6,958
patients representing 1. 7 percent/year, as opposed to 241
events of the 7,004 patients in the warfarin group (2.2 percent/year). Relevant nonmajor bleeding occurred in 1,475
patients in the rivaroxaban group and 1,449 patients in the
warfarin group, but the difference was not clinically significant (P=0.44). Major bleeding rates also occurred at similar
rates between the two treatment groups (P=0.58). Fatal
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bleeding rates of intracranial hemorrhage were significantly
lower in patients of the rivaroxaban group (0.5 percent versus 0.7 percent; P=0.02)). Decreases in hemoglobin and major gastrointestinal bleeding were more common in the rivaroxaban group than in the warfarin group. In evaluation of
the secondary outcomes in the as-treated population, MI and
death occurred less frequently in the rivaroxaban group than
the warfarin group, but the difference was not clinically significant. Results were similar in the intention-to-treat analysis of secondary outcomes. Findings concluded that rivaroxaban was noninferior to warfarin in primary analysis. In the
analysis of patients receiving at least one dose of study drug,
rivaroxaban was found to be superior to warfarin.
Rivaroxaban dosing is specific for each individual indication.
For the treatment of DVT and PE, it is recommended that the
patient initially be started on lS mg twice daily with food for
21 days, and then the patient should have their dose modified to 20 mg daily with food. 22 For the prevention of recurrent DVT and PE after six months of treatment, the suggested
regimen is 20 mg once daily with food. For postoperative
DVT thromboprophylaxis, it is recommended that therapy be
initiated after hemostasis has been established six to 10
hours postoperatively. In knee replacement, the recommended dosage is 10 mg once daily for 12 to 14 days (maximum
3S days). For hip replacement, 10 mg once daily is appropriate for 10 to 14 days (maximum 3S days). In the treatment of
nonvalvular atrial fibrillations, 20 mg once daily with the
evening meal is recommended. In cases of DVT and PE
prophylaxis and treatment, dose reduction is recommended
in older adults with CrCl between 30 and SO mL/min. If the
CrCl is <30 mL/min, avoid use of rivaroxaban. In patients
with nonvalvular atrial fibrillation, no dosage adjustment is
necessary if the CrCl is >SO mL/min. If the CrCl is lS to SO
mL/min, a dose reduction to lS mg is recommended. Use is
discouraged if the CrCl is <lS mL/min or if the patient has
end stage renal disease (ESRD) requiring dialysis. Beer's criteria recommend a dose reduction in patients over the age of
6S years with CrCI between 30 and SO mL/min and discourage use in patients with CrCI <30 mL/min.
There is strong evidence to support the use of rivaroxaban in
patients with atrial fibrillation and at least one additional
stroke risk factor.20 Newer agents like rivaroxaban are indicated for this condition due to the fact that routine lab monitoring is not required, which has become a key advantage for
this therapy. It has been proven to be as effective as warfarin
in this indication. Common side effects of rivaroxaban include bleeding, nausea and fatigue. 22 Renal function should
be monitored at baseline and regularly during therapy.20
Rivaroxaban has a black box warning stating that patients
with nonvalvular atrial fibrillation may have an increased
risk of thrombotic events if therapy is discontinued without
adequate tapering of therapy through use of additional anticoagulation. Additionally, this warning states that patients
who are receiving neuraxial anesthesia or are undergoing
spinal puncture have an increased risk of epidural or spinal
hematoma while taking rivaroxaban. This medication is contraindicated in patients with hypersensitivity to rivaroxaban
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or pathological bleeding. Rivaroxaban therapy is not recommended in those patients who are pregnant or breastfeeding.
One of the disadvantages of rivaroxaban over warfarin, aside
from increased cost, is that there is currently no specific reversal agent for rivaroxaban in the event of severe hemorrhage.23 Upon suspected bleed associated with rivaroxaban,
further evaluate the patient for signs and symptoms of blood
loss, and consider the need for blood or blood products if
necessary. Partial reversal has been seen in healthy volunteers after administration of prothrombin complex concentrates. One study demonstrated that prothrombin complex
concentrates (Cofact) nearly neutralized the anticoagulant
effects of rivaroxaban in healthy patients. However, further
research needs to be targeted in this area.2 4
Apixaban
Apixaban (Eliquis®) is also a factor Xa inhibitor approved by
the FDA in 2012.20 Apixaban is indicated for the prevention
of SE and stroke in patient populations with nonvalvular atrial fibrillation. It can also be used for the treatment of DVT
and PE, as well as thromboprophylaxis of postoperative DVT.
Apixaban provides an advantage over warfarin due to warfarin's narrow therapeutic range, drug-drug and drug-food
interactions, and required monitoring.
Apixaban inhibits formation of fibrin clots and platelet activation through direct reversible inhibition of both the free
and bound form of factor Xa. 2s It is predominantly metabolized in the liver by CYP3A4/S enzymes and interacts with
p-glycoprotein. Due to its metabolism by this enzyme, there
are specific drug interactions with other inducers of CYP3A4
and p-glycoprotein.20 Avoid apixaban in combination with
CYP3A4 inducers like carbamazepine, phenytoin and rifampin. It is not recommended in patients with severe liver impairment, active pathological bleeding. prosthetic heart valves
and those pregnant or breastfeeding. Additionally, use of nonsteroidal anti-inflammatory drugs and clopidogrel should be
avoided with apixaban due to increased risk of bleeding
In the ARISTOTLE trial, a randomized, double-blind, doubledummy trial, patients were randomly assigned either apixaban or dose-adjusted warfarin.26 The objective of this study
was to prove the noninferiority of apixaban as compared to
warfarin in reducing the incidence of stroke in patients with
nonvalvular atrial fibrillation and at least another risk factor.
Secondary outcomes were death from any cause and rate of
MI. Patients enrolled in this study had at least two documented episodes of atrial fibrillation or atrial flutter by electrocardiogram. Other risk factors included age of at least 7S years,
previous incidence of stroke, transient ischemic attack, heart
failure, diabetes or hypertension. This trial also measured
the safety outcome of major bleeding as well as whether
apixaban was superior to warfarin with respect to reduction
of stroke and reduction in major bleeding.
Apixaban was given twice daily in either 2.S mg or S mg doses.26 There was a significant difference in death between the
apixaban and warfarin treatment groups. The rate of death in
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the apixaban group was 3.52 percent as compared to 3.94
percent in the warfarin group (p=0.047). Stroke or SE
occurred in 212 patients in the apixaban group and 265 patients of the warfarin group, showing that apixaban demonstrated a significant lower incidence of the primary outcomes
(p<0.001). Hemorrhagic stroke was 49 percent lower in the
apixaban group than the warfarin group. Ischemic stroke
was 8 percent lower in the apixaban group than the warfarin
group. Approximately 84 patients in the apixaban group experienced fatal or disabling stroke as compared to 117 patients in the warfarin group (p=0.01). Secondary outcomes
also showed similar differences among treatment groups.
Death from any cause (3.52 percent versus 3.94 percent),
rate of death from cardiovascular events (1.80 percent versus 2.02 percent) and rate of death from noncardiovascular
events (1.14 percent vs. 1.22 percent) was significantly lower
in the apixaban group than warfarin group.
The rate of MI was lower in the apixaban group, but the difference was not statistically significant (P=0.37).26 Major
bleeding occurred at a statistically significantly higher rate in
the warfarin group than the apixaban group (p<0.001). According to the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) criteria for bleeding, there was a
greater reduction in risk of bleeding in the apixaban group.
Fewer patients experienced intracranial hemorrhage and
overall major bleeding in the apixaban group than the warfarin group. Rates of adverse events were similar among
groups. Overall, this study concluded that there was a significant reduction in risk of stroke or SE in treatment with apixaban over treatment with warfarin. No unexpected side effects
were noted in the apixaban group. While the authors noted
that warfarin is still extremely efficacious in the prevention
of stroke in patients with atrial fibrillation, they identified
that apixaban did not have many of the issues seen in
warfarin therapy. The dose that was most efficacious for the
prevention of stroke in these study patients was 5 mg twice
daily. This study concluded that apixaban was noninferior to
warfarin in preventing the primary outcomes.
Apixaban is normally dosed at 5 mg twice daily for atrial fibrillation.zo It is recommended that the dose be reduced to
2.5 mg twice daily if the patient is 80 years of age or older,
has a bodyweight of 132 pounds or less or has a serum creatinine level of 1.5 mg/dL or above. Currently there is no data
for dosing in patients on dialysis with a CrCI < 15 mL/min or
patients with liver impairment. For the treatment of DVT and
PE 10 mg twice daily for seven days followed by 5 mg twice
daily maintenance is recommended.ZS To reduce the risk of
recurrence of DVT and PE, 2.5 mg twice daily is recommended for at least six months following treatment for DVT. In
postoperative prophylaxis, initiate 2.5 mg twice daily 12 to
24 hours postoperatively in both knee and hip replacement.
The most common adverse effect of apixaban is bleeding.
However, clinically relevant bleeding comprises only a small
portion of this adverse event.zo,zs Similar to rivaroxaban,
there is no specific reversal agent for apixaban at this time.zo
The clinician and patient should monitor for signs of bleedSummer 2016 Volume 7, Issue 3
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ing during treatment. Currently, studies are being conducted
to investigate potential reversal agents in patients receiving
this therapy. 24 We should expect to see more research on this
topic in the future.
Apixaban is best suited for patients who are unable or unwilling to adhere to the monitoring parameters associated
with vitamin K antagonists like warfarin.27 While warfarin
requires strict monitoring of specific blood parameters, apixaban does not require such monitoring. This criteria should
be considered when selecting the appropriate therapy for
patients eligible for anticoagulation therapy.

Role of the Pharmacist
With the recent approval of advanced anticoagulation therapy, the pharmacist must make it a priority to keep up to date
on changes.zs Additionally, the pharmacist must be able to
identify the advantages and disadvantages of newer therapies as compared to traditional therapies like warfarin in
making patient specific recommendations. Refer to Table 1
as a guide in recommending appropriate anticoagulation
therapy. Pharmacists certainly continue to play a large role
in management of patients requiring anticoagulation therapy. For pharmacists specifically working in the area of anticoagulation, such as clinics, a national certification exam is
available through the National Certification Board for Anticoagulation Providers. Pharmacists will continue to play a crucial role in assessing patients for appropriate therapy and
adjusting accordingly to provide exceptional patient care.
Impact of Patient Care and Counseling Points
Anticoagulation therapy provides a large area for pharmacist
intervention. Anticoagulation therapy is common, especially in
patients suffering from congenital heart defects, heart valve
replacements, surgery and other heart and coagulation related
disorders. 29 Patients receiving anticoagulation therapy who
become pregnant need to take special precautions and be
monitored. The cardiologist and the obstetrician of the patient
should address her specific and individualized management.
While frequent monitoring is a drawback of warfarin use,
some competent, well-controlled patients may be eligible to
self-monitor their INR at home.zo Point-of-care monitors,
which are normally used in clinics and physicians' offices,
may be provided to patients for home use. Patient selftesting has demonstrated an increase in INR control, decreased thromboembolic events, improved quality of life and
patient satisfaction with treatment. Self-testing may not be
appropriate in all patients taking warfarin. Patients should
not be considered for self-testing if they do not demonstrate
competency, are treated with warfarin for less than six
months, have atypical INR target ranges, have intellectual
impairment, have a known drug or alcohol problem or have
language barriers that would impede with communication. It
is important to consider these criteria when deciding if a patient is eligible for self-monitoring of INR.
Table 2 identifies important counseling points for pharmacists for each individual therapy. It is crucial to educate these
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Table 1. Comparison of Anticoagulation Therapy for Pharmacist Recommendation.6,10,13-14
Anticoagulant

Dosing

FDA Approved
Indications

Monitoring

Once
daily;
with or
without
food 10

Prophylaxis and treatment ofthromboembolic disorders and
embolic complications
arising from Afib or
cardiac valve replacement; adjunct to reduce risk of systemic
embolism after myocardial infarction.10

No dosage adjustment necessary.10
Howeve r, patients with renal failure
have an increased risk of bleeding
complications; monitor closely.

INR should be monitored
at least every one to four
weeks.10 When products
that affect warfarin are
initiated, discontinued,
or taken irregularly,
additional INR testing
should be performed.

Once
daily;
with food

DVT prophylaxis and
treatment; PE prophy!axis and treatment;
nonvalvular Afib

DVT&PE:
CrCl > 30 mL/min - no dose adjustmentAvoid use in CrCI < 30 mL/min
Nonvalvular Afib:
CrCl > SO mL/min - no dose
adjustment
CrCI lS to SO mL/min, reduce dose
to lS mg once daily with evening
meal.
Avoid use ifCrCl < lS mL/min
Postoperative thromboprophylaxis:
CrCl > SO mL/min - no adjustment
Use with caution in CrCl 30 to SO
mL/min
Avoid use in CrCl < 30 mL/min

Routine lab monitoring
not required

Twice
daily;
with or
without
food

DVT prophylaxis and
treatment; PE prophy!axis and treatment;
nonvalvular Afib

DVT&PE:
No dose adjustment

Routine lab monitoring
not required

Nonvalyular Afib:
sCR < 1.S mg/dL no adjustment
necessary unless > 80 years of age
and body weight.$_ 60 kg - reduce
dose to 2.6 mg twice daily.
sCr.:::. LS mg/dL and either.:::. 80
years of age or body weight< 60 kg 2.5 mg twice daily

Not recommended in
severe liver impairment

Twice
daily;
with or
without
food

DVT treatment and
prophylaxis; nonvalvuJar AFib; postoperative
thromboprophylaxis

CrCI > 30 mL/min - no adjustment
unless CrCl, SO mL/min and patient
is receiving concomitant P-gp
inhibitors - avoid coadministration

Routine monitoring not
required. Can use aPTT,
ECT or TT if desired

Warfarin

Riva roxaban

Apixaban

Dabigatra n

Renal dosing

Avoid use ifCrCl <30 ml/min
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Table 1 (continued). Comparison of Anticoagulation Therapy for Pharmacist Recommendation.6,10,13-14
Reversal Agent

Adverse Effects

Interactions

Procedure Considerations

Vitamin K, and in severe bleeding complications PCC or FFP is
also used6.10,13

Increased risk for
bleeding10

Many drug and food interactions,
but dose can be adjusted for interactions. 10

Hold S days prior to
surgery.10 If urgent
procedure, may administer
low-dose IV or oral vitamin
K.

Continue warfarin during
minor dental and dermatological procedures or
cataract surgery.

No specific reversal agent
May consider PCC, activated
PCC or recombinant factor VIia

CYP3A4 and P-gp drug interactions

Fatigue, nausea,
increased bleeding
risk

Longer cessation may be
required based on clinical
judgment

Do NOT use dialysis

No specific reversal agent

Hold 24 hours prior to
surgery

Bleeding, nausea,
bruising

CYP3A4 and P-gp drug interactions

Hold 24 to 48 hours prior
to surgery

Hemorrhage, dyspepsia

P-gp drug interactions

CrCl ;;::SQ mL/minute: Hold
1 to 2 days prior to surgery
CrCl <SO mL/minute: Hold
3 to S days prior to surgery
Consider holding more
than S days before major
surgery spinal puncture, or
insertion of a spinal or
epidural catheter or port

May consider PCC, activated
PCC or recombinant factor VIia
for major bleeding
Do NOT use dialysis
Activated charcoal may be used
if ingestions within 2-4 hours of
presentation

Idarucizumab
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Table 2. Counseling Guide for Pharmacists in Anticoagulation Therapy.10,14,22,2s
Anticoagulant
Th erapy

Monitoring/ Expectations

Indication
The medication is used to
treat blood clots and is
used to thin the blood so
more clots will not form.

Warfarin

The patient may notice more bleeding or bruising.
Common side effects include fatigue, nausea or abdominal pain.
This medication can cause severe bleeding-it's important to monitor for
signs of extreme bruising and bleeding like bloody stools, blood in the
urine, excessive dizziness and severe weakness.
If the patient falls and/or hits their head, advise patient to seek medical
attention immediately.
This medication requires frequent blood work monitoring (lNR) by the
physician. It is important to keep these appointments.

The medication is used to
treat blood clots and is
used to thin the blood so
more clots will not form.

The patient may notice more bleeding or bruising.
Spinal or epidural procedures are more likely to have bleeding issues in
that area. While this effect is rare, if it does happen it can cause paralysis
in some cases. Consult physician.
Risk of bleeding is increased with aspirin or NSAIDs.

Rivar oxaban

While there is no routine monitoring for this drug, it is important to have
regular blood work done.
If the patient falls and/or hits their head, advise patient to seek medical
attention immediately.

The medication is used to
treat blood clots and is
used to thin the blood so
more clots will not form.

Apixaban

The patient may notice more bleeding or bruising.
Other common side effects of this medication include nausea and anemia.
Spinal or epidural procedures are more likely to have bleeding issues in
that area. While this effect is rare, if it does happen it can cause paralysis
in some cases. Consult physician.
Risk of bleeding is increased with aspirin or NSAIDs.
While there is no routine monitoring for this drug, it is important to have
regular blood work done.
If the patient falls and/ or hits their head, advise patient to seek medical
attention immediately.

The medication is used to
treat blood clots and is
used to thin the blood so
more clots will not form.

The patient may notice more bleeding or bruising.
Other common side effects of this medication include upset stomach or
heartburn.
Spinal or epidural procedures are more likely to have bleeding issues in
that area. While this effect is rare, if it does happen it can cause paralysis
in some cases. Consult physician.

Dabigatran

Risk of bleeding is increased with aspirin or NSAIDs.
While there is no routine monitoring for this drug, it is important to have
regular blood work done.
If the patient falls and/or hits their head, advise patient to seek medical
attention immediately.

42

THE PHARMACY AND WELLNESS REVIEW

Summer 2016 Volume

7,

Issue 3

Comparison of Long-Term Oral Anticoagulation Therapies Including Newly Approved Reversal Agent for Dabigatran

Missed Dose
If a dose is missed, take the dose as soon as patient thinks of it if
on the same day as the missed dose.
If it is close to the time of the next dose, skip to missed dose and
go back to normal schedule.

Do not take extra doses or more than one dose in the same day.
Don't stop taking this medication unless directed by a doctor.
Stopping the drug increases risk of blood clots.

For dosing 15 mg twice daily and miss a dose, take the missed
dose as soon as patient thinks of it to get 30 mg in for the day. In
this case, the patient can take two doses at the same time. Return
to normal time the following day.
For all other doses: If a dose is missed, take the dose as soon as
patient thinks of it if on the same day as the missed dose. If it is
close to the time of the next dose, skip to missed dose and go back
to normal schedule. Do not take extra doses or more than one
dose in the same day.

Cardiovascular

Other Precautions
The patient may notice bleeding of the gums or bleeding
while shaving. Recommend a soft bristle toothbrush or
electric razor.
Inquire about new medications or dietary supplements.
Many foods may interact with this medication. Keep the
diet consistent to minimize fluctuations in lab values.
Avoid excessive consumption ofleafy greens, green tea
and alcohol.

The patient may notice bleeding of the gums or bleeding
while shaving. Recommend a soft bristle toothbrush or
electric razor.
Take this medication with food and a full glass of water in
the evening.
There are no food interactions with this medication.

Don't stop taking this medication unless directed by a physician.
Stopping the drug can increase risk of blood clots.
If a dose is missed, take the dose as soon as patient thinks of it if
on the same day as the missed dose.

The patient may notice bleeding of the gums or bleeding
while shaving. Recommend a soft bristle toothbrush or
electric razor.

If it is close to the time of the next dose, skip the missed dose and
go back to normal schedule.

Take this medication with or without food.

Do not take extra doses or more than one dose in the same day.

There are no food interactions with this medication.

Don't stop taking this medication unless directed by a physician.
Stopping the drug can increase risk of blood clots.

If a dose is missed, take the dose as soon as patient thinks of it if
on the same day as the missed dose.
If it is less than 6 hours until the next dose, skip the dose and.
return to normal schedule.

Do not take extra doses or more than one dose in the same day.
Don't stop taking this medication unless directed by a physician.
Stopping the drug can increase risk of blood clots.

The patient may notice bleeding of the gums or bleeding
while shaving. Recommend a soft bristle toothbrush or
electric razor.
Take this medication with or without food and with a full
glass of water.
Do not store this medication in a pill box or organizer.
It is important to leave this medication in its original
container.
Throw away any unused capsules after four months.
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patients to manage their conditions and reduce their risk of
stroke and other cardiovascular events.
Economic Concerns
The cost of these new anticoagulant medications is offset by
both adverse effect mitigation and the economic impact of
cardiovascular events such as stroke. In 2008, an alarming
780,000 patients experienced a stroke, costing an estimated
$65.5 billion. While it is important to note that not all strokes
are caused by atrial fibrillation, prevention of stroke secondary to atrial fibrillation through anticoagulation therapy is
crucial. The economic burden of bleeding in patients receiving anticoagulation therapy is limited in comparison to the
costs associated with stroke. In 2011, studies estimated the
cost of these bleeding events to be around $35,000; however,
the severity of the bleed will ultimately determine the true
impact.
For over a decade, warfarin therapy has consistently been
more cost-effective compared to aspirin therapy.3o Warfarin
is cost-effective in patients at least 65 years of age with atrial
fibrillation and at least one additional risk factor for stroke.
These risk factors include history of transient ischemic attack (TIA), hypertension, diabetes and heart disease. Even in
patients without additional risk factors for stroke, the costeffectiveness of warfarin over aspirin remains high.
Dabigatran is certainly more expensive than warfarin due to
a higher acquisition cost, raising the question of whether or
not it is a cost-effective option as compared to warfarin.3o
One model studied the cost-effectiveness of dabigatran using
CHADS2 score based on the presence or absence of risk factors. Dabigatran 150 mg dosed twice daily was determined to
be cost-effective in patients older than 65 years who had at
least one point based on their CHADS2 score with no contraindications against dabigatran therapy. However, 110 mg
daily was not determined to be cost-effective.
Another model by Shah and Gage estimated the cost of
dabigatran at approximately $9 per day.3o Cost-effectiveness
was measured over 20 years of treatment. In patients with a
CHADS2 score of 0, aspirin was preferred over dabigatran
therapy in terms of cost-effectiveness. In patients with a
CHADS2 score of 1 or 2, warfarin was preferred over
dabigatran unless the patient was at high risk of bleeding or
was rarely within therapeutic range while on warfarin. If the
patient had a CHADS2 score of 3 or higher, 150 mg of
dabigatran was preferred in terms of cost-effectiveness. This
recommendation stands regardless of bleeding risk or time
within target INR. Dabigatran dosed at 110 mg twice daily
was determined not to be cost-effective in this model. The
third model studying the cost-effectiveness of dabigatran
compared dosing of 150 mg in patients who had previously
experienced a stroke or TIA This study determined that 150
mg twice daily was not cost-effective as compared to warfarin.
Rivaroxaban's cost-effectiveness was studied in patients at a
high risk of stroke.30 Over a time period of 35 years or until
death, it was found that rivaroxaban 20 mg daily is more
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cost-effective than warfarin therapy if the patient was at
least 65 years of age and at a high risk of stroke. The authors
noted that this effectiveness was also sensitive to change in
risk of stroke.
Apixaban's cost-effectiveness was studied in three separate
models.3o In the first Markov model, the cost-effectiveness of
apixaban was studied compared to aspirin in patients 70
years of age with atrial fibrillation, high risk of stroke, low
risk of bleeding or not suitable for warfarin therapy. Apixaban was more costly than aspirin in the first year. However,
after 10 years the data showed a reversal in this conclusion.
Apixaban became more cost-effective over longer periods
of time. The second Markov model studied the costeffectiveness of apixaban compared to warfarin in patients
65 years of age with atrial fibrillation and a CHADS2 score of
2. Apixaban was determined to be more cost-effective over a
timeline of 35 years. In a third model, the subject of study
was the cost reduction of clinical events such as major bleeding associated with anticoagulation oral therapy. It was determined that the medical cost reduction was significantly
more with newer anticoagulation therapy compared to warfarin. The yearly medical cost of these events with
dabigatran, rivaroxaban and apixaban were $1,905; $1,995;
and $1,598, respectively, versus $2,084 with warfarin.
Future of Anticoagulation Therapy
In the future, pharmacists should expect to see further advancements in anticoagulation. Specifically, studies are currently being conducted to potentially identify a reversal
agent for rivaroxaban and apixaban.24 While there have been
numerous advancements in medications in the last two decades, it is expected that there will be an increased focus on
disease prevention and patient safety with this therapy. This
focus is primarily due to quality care assessments and their
direct impact on hospital accreditation and reimbursement.
Overall, anticoagulation therapy provides a number of opportunities for drug development, further improvements in
disease state management and promotion of health care professional collaboration.
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